Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · Real-Time Price · USD
5.65
-0.23 (-3.91%)
At close: Jul 8, 2026, 4:00 PM EDT
5.92
+0.27 (4.78%)
After-hours: Jul 8, 2026, 4:10 PM EDT
Champions Oncology Employees
Champions Oncology had 213 employees as of April 30, 2025. The number of employees increased by 3 or 1.43% compared to the previous year.
Employees
213
Change (1Y)
3
Growth (1Y)
1.43%
Revenue / Employee
$272,042
Profits / Employee
-$11,000
Market Cap
78.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Apr 30, 2025 | 213 | 3 | 1.43% |
| Apr 30, 2024 | 210 | -20 | -8.70% |
| Apr 30, 2023 | 230 | 0 | - |
| Apr 30, 2022 | 230 | 36 | 18.56% |
| Apr 30, 2021 | 194 | 51 | 35.66% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| MindWalk Holdings | 102 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| Entera Bio | 22 |
| Gain Therapeutics | 21 |
| iBio, Inc. | 20 |
| LeonaBio | 19 |
CSBR News
- 3 months ago - Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 - Accesswire
- 3 months ago - Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy - Accesswire
- 4 months ago - Champions Oncology Earnings Call Transcript: Q3 2026 - Transcripts
- 4 months ago - Champions Oncology Quarterly report: Q3 2026 - Filings
- 4 months ago - Champions Oncology Earnings release: Q3 2026 - Filings
- 4 months ago - Champions Oncology Reports Revenue of $16.6 Million - Accesswire
- 4 months ago - Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026 - Accesswire
- 7 months ago - Champions Oncology Earnings Call Transcript: Q2 2026 - Transcripts